Navigation Links
Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering
Date:10/25/2007

CLEARWATER, Fla., Oct. 25 /PRNewswire-FirstCall/ -- Lincare Holdings Inc. (Nasdaq: LNCR) today announced the pricing of $250 million principal amount of convertible senior debentures due 2037 - Series A (the "Series A Debentures") and $250 million principal amount of convertible senior debentures due 2037 - Series B (the "Series B Debentures" and together with the Series A Debentures, the "Debentures"), in each case to be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lincare granted the initial purchasers of the Debentures an option to purchase an additional $25 million aggregate principal amount of the Series A Debentures and an option to purchase an additional $25 million aggregate principal amount of the Series B Debentures, in each case, solely to cover overallotments, if any.

The Debentures will pay interest semiannually at a rate of 2.75 percent per year. The Debentures will be Lincare's unsecured and unsubordinated obligations and will be convertible under specified circumstances based upon a base conversion rate, which, under certain circumstances, will be increased pursuant to a formula that is subject to a maximum conversion rate. Upon conversion, holders of the Debentures will receive cash up to the principal amount, and any excess conversion value will be delivered in shares of Lincare common stock or in a combination of cash and shares of common stock, at Lincare's option. The initial base conversion rate for the Debentures is 19.5044 shares of Lincare common stock per $1,000 principal amount of Debentures, equivalent to an initial base conversion price of approximately $51.27 per share. In addition, if at the time of conversion the applicable price of Lincare's common stock exceeds the base conversion price, holders of the Series A Debentures and Series B Debentures will receive an additional number of shares of Lincare common stock per $1,000 principal amount of the Debentures, as determined pursuant to a specified formula. The initial base conversion price for the Debentures represents a premium of 52.5 percent, based on the closing price of Lincare's common stock of $33.62 per share on October 25, 2007.

Lincare will have the right to redeem the Series A Debentures and the Series B Debentures at any time after November 1, 2012 and November 1, 2014, respectively. Holders of the Debentures will have the right to require Lincare to repurchase for cash all or some of their Debentures upon the occurrence of certain fundamental change transactions or on certain specified dates.

The Debentures and the shares of Lincare common stock issuable upon conversion of the Debentures have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

Lincare intends to use up to approximately $150 million of the net proceeds from the issuance of the Debentures to acquire shares of its common stock concurrently with the offering and it may use additional proceeds for further stock repurchases following the offering. Lincare intends to use the remaining proceeds to fund selective business acquisitions and for general corporate purposes, including the repayment of debt or other obligations.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the Debentures and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

Statements in this release concerning future results, performance or expectations are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All forward-looking statements, including the statements regarding Lincare's expectation to sell Debentures and repurchase shares of its common stock, included in this document are subject to risks and uncertainties and are based upon information available to Lincare as of the date hereof. Lincare cannot guarantee that any of these transactions will be consummated and assumes no obligation to update any such forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, including general market risks, that may cause Lincare's ability to complete the offering of the Debentures and the repurchase of its common stock to be materially different from any results, performance or achievements that are expressed or implied by any forward-looking statements. In some cases, forward-looking statements that involve risks and uncertainties contain terminology such as "may," "will," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or variations of these terms or other comparable terminology.


'/>"/>
SOURCE Lincare Holdings Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Drug Prices in India to be Monitored - NPPA to Tie up with ORG
2. Delhi Sees Sharp Decline In Chicken Prices
3. Prices of eggs, egging its way upwards
4. Chicken Prices Show an Upward Trend – Consumers, Not Scared Chicken Anymor
5. Drug Prices Hit The Roof In Malaysia
6. Drug Prices Rising Faster Than Inflation
7. Brand Name Drug Prices Zoom
8. Impact of New Drug Retail Prices Soon: Paswan
9. List of 886 Drug Prices that has been Reduced by Govt. of India
10. Fixation of Prices of Drugs
11. New Drugs Prices Control Order to Be Issued After Finalisation of New Pharmaceutical Policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology: